The endocannabinoid system, a new gatekeeper in the pharmacology of human hepatocellular carcinoma

Ebrahimi, Nader; Far, Nazanin Pazhouhesh; Fakhr, Siavash Seifollahy; Faghihkhorasani, Ferdos; Miraghel, Seyed Ali; Chaleshtori, Siavash Rahimian; Rezaei-Tazangi, Fatemeh; Beiranvand, Sheida; Baziyar, Payam; Sadat, Manavi, Mahdokht; Zarrabi, Ali; Nabavi, Noushin; Ren, Jun; Aref, Amir Reza

doi:10.1016/j.envres.2023.115914

Cited by 8 publications

(5 citation statements)

References 191 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phytocannabinoids and substances that elevate endogenous cannabinoid levels are considered potential drugs for the treatment of HCC [35]. The use of cannabinoids has been linked to a 55% reduction in the likelihood of developing HCC [36], with CBD demonstrating higher safety compared to other cannabinoids [37].…”

Section: Hepatocellular Carcinoma and Metastasismentioning

confidence: 99%

The Role of Cannabidiol in Liver Disease: A Systemic Review

Chen,

Kim

2024

IJMS

View full text Add to dashboard Cite

Cannabidiol (CBD), a non-psychoactive phytocannabinoid abundant in Cannabis sativa, has gained considerable attention for its anti-inflammatory, antioxidant, analgesic, and neuroprotective properties. It exhibits the potential to prevent or slow the progression of various diseases, ranging from malignant tumors and viral infections to neurodegenerative disorders and ischemic diseases. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and viral hepatitis stand as prominent causes of morbidity and mortality in chronic liver diseases globally. The literature has substantiated CBD’s potential therapeutic effects across diverse liver diseases in in vivo and in vitro models. However, the precise mechanism of action remains elusive, and an absence of evidence hinders its translation into clinical practice. This comprehensive review emphasizes the wealth of data linking CBD to liver diseases. Importantly, we delve into a detailed discussion of the receptors through which CBD might exert its effects, including cannabinoid receptors, CB1 and CB2, peroxisome proliferator-activated receptors (PPARs), G protein-coupled receptor 55 (GPR55), transient receptor potential channels (TRPs), and their intricate connections with liver diseases. In conclusion, we address new questions that warrant further investigation in this evolving field.

show abstract

Section: Hepatocellular Carcinoma and Metastasismentioning

confidence: 99%

The Role of Cannabidiol in Liver Disease: A Systemic Review

Chen,

Kim

2024

IJMS

View full text Add to dashboard Cite

show abstract

“…NcRNAs are types of RNAs grouped into short (19-31 nucleotides), mid (20-200 nucleotides), and long (>200 nucleotides) (Ebrahimi, Far, et al, 2023;Ebrahimi, Fardi, et al, 2023;Ebrahimi, Hakimzadeh et al, 2023). NcRNAs are crucial regulators involved in many vital processes, such as cell metabolism, apoptosis, proliferation, posttranscriptional modifications, and differentiation.…”

Section: Ncrnas: Biogenesis and Roles In Cancermentioning

confidence: 99%

“…NcRNAs are crucial regulators involved in many vital processes, such as cell metabolism, apoptosis, proliferation, posttranscriptional modifications, and differentiation. These RNAs can act as tumor suppressors or oncogenes (Ebrahimi, Far, et al, 2023;Ebrahimi, Fardi, et al, 2023;Ebrahimi, Hakimzadeh et al, 2023).…”

Section: Ncrnas: Biogenesis and Roles In Cancermentioning

confidence: 99%

“…In general, tumor resistance to chemotherapeutics is categorized into acquired and intrinsic types (Ebrahimi et al, 2024). Acquired resistance is attributed to the molecular changes of cancer cells following therapy to improve cell survival (Ebrahimi, Far, et al, 2023;Ebrahimi, Fardi, et al, 2023;Ebrahimi, Hakimzadeh et al, 2023). This process is triggered by diverse processes, including (1) driver oncogene regulation (e.g., promotion of EGFR T790M mutation), (2) stimulation of prosurvival signaling (such as signaling associated with cell metabolism, cell proliferation, autophagy or apoptosis), and (3) adaptability of tumor microenvironment following the initiation of therapy (Chen, Dragomir, et al, 2022;Chen, Wang, et al, 2022).…”

Section: Role In Chemoresistancementioning

confidence: 99%

“…For HCC treatment, it has been recommended some therapeutic methods, for example, liver transplantation, the most efficient modality for HCC, but the lack of adequate donated organs considerably limits this method (van der Meeren et al, 2023). Other approaches, like surgery, chemotherapy, and radiotherapy, are associated with several serious side effects, such as the toxicity of the different body systems (e.g., the immune system) and the advancement of secondary tumors (Ebrahimi, Far, et al, 2023;Ebrahimi, Fardi, et al, 2023;Ebrahimi, Hakimzadeh et al, 2023;Minaei et al, 2023). Epigenetics can help to understand the mechanisms of commencement and progress of HCC; accordingly, it can be used for better designing therapeutic or diagnostic approaches (Pourhamzeh et al, 2023).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Noncoding RNAs and programmed cell death in hepatocellular carcinoma: Significant role of epigenetic modifications in prognosis, chemoresistance, and tumor recurrence rate

Arefnezhad,

Ashna,

Rezaei‐Tazangi

et al. 2024

Cell Biology International

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common type of liver cancer with a high death rate in the world. The molecular mechanisms related to the pathogenesis of HCC have not been precisely defined so far. Hence, this review aimed to address the potential cross‐talk between noncoding RNAs (ncRNAs) and programmed cell death in HCC. All related papers in the English language up to June 2023 were collected and screened. The searched keywords in scientific databases, including Scopus, PubMed, and Google Scholar, were HCC, ncRNAs, Epigenetic, Programmed cell death, Autophagy, Apoptosis, Ferroptosis, Chemoresistance, Tumor recurrence, Prognosis, and Prediction. According to the reports, ncRNAs, comprising long ncRNAs, microRNAs, circular RNAs, and small nucleolar RNAs can affect cell proliferation, migration, invasion, and metastasis, as well as cell death‐related processes, such as autophagy, ferroptosis, necroptosis, and apoptosis in HCC by regulating cancer‐associated genes and signaling pathways, for example, phosphoinositide 3‐kinase/Akt, extracellular signal‐regulated kinase/MAPK, and Wnt/β‐catenin signaling pathways. It seems that ncRNAs, as epigenetic regulators, can be utilized as biomarkers in diagnosis, prognosis, survival and recurrence rates prediction, chemoresistance, and evaluation of therapeutic response in HCC patients. However, more scientific evidence is suggested to be accomplished to confirm these results.

show abstract